[Activation of macrophages from lymphoma-bearing mice by liposome mediated intraperitoneal IL-2 and IL-6 gene therapy].
OBJECTIVE
To investigate the antitumor mechanism of interleukin-2 (IL-2) and interleukin-6 (IL-6) gene therapy.


METHODS
IL-2 DNA liposome and IL-6 DNA liposome were i. p injected into EL-4 lymphoma-bearing mice. The function of macrophages from the mice was assayed.


RESULTS
The cytotoxicity, the MHC Ia expression and IL-1 and TNF secretion of the macrophage were all augmented after i.p injection of IL-2 or IL-6 DNA liposomes, and more efficient activation was observed in the mice treated with IL-2 DNA liposome. IL-2 combined with IL-6 gene therapy showed the maximal activation of macrophages from the lymphoma-bearing mice.


CONCLUSIONS
IL-2 and IL-6 gene therapy can relieve the suppression of macrophages of the lymphoma-bearing mice, and activate the antitumor immune responses efficiently.
Wang
Q
Q
Department of Immunology, Second Military Medical University, Shanghai 200433.
Cao
X
X
Wang
J
J
D000818:Animals; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D015316:Genetic Therapy; D015234:HLA-A Antigens / Q000378:metabolism; D007375:Interleukin-1 / Q000378:metabolism; D007376:Interleukin-2 / Q000737:chemistry / Q000235:genetics* / Q000627:therapeutic use; D015850:Interleukin-6 / Q000737:chemistry / Q000235:genetics* / Q000627:therapeutic use; D008081:Liposomes; D008223:Lymphoma / Q000235:genetics* / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D008262:Macrophage Activation / Q000276:immunology*; D008264:Macrophages / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008297:Male; D051379:Mice; D010537:Peritoneum / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D015234:HLA-A Antigens; D007375:Interleukin-1; D007376:Interleukin-2; D015850:Interleukin-6; D008081:Liposomes; D014409:Tumor Necrosis Factor-alpha